Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights

Blood. 2017 Dec 7;130(23):2569-2572. doi: 10.1182/blood-2017-08-802413. Epub 2017 Oct 26.

Authors

Amrom E Obstfeld¹, Noelle V Frey^{2

3}, Keith Mansfield⁴, Simon F Lacey^{1

5}, Carl H June^{1

5}, David L Porter^{2

3}, Jan J Melenhorst^{1

5}, Mariusz A Wasik¹

Affiliations

¹ Department of Pathology and Laboratory Medicine.
² Department of Medicine.
³ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
⁴ Novartis Institute for Biomedical Research, Cambridge, MA; and.
⁵ Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

PMID: 29074500
DOI: 10.1182/blood-2017-08-802413

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19 / immunology
Cytokines / metabolism*
Endothelial Cells / pathology
Fatal Outcome
Humans
Immunotherapy, Adoptive / adverse effects*
Interleukin-6 / analysis
Male
Middle Aged
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Receptors, Antigen, T-Cell / genetics*
Receptors, Antigen, T-Cell / immunology

Substances

Antigens, CD19
Cytokines
IL6 protein, human
Interleukin-6
Receptors, Antigen, T-Cell